Germany
Eisai: Fycompa decision ‘deeply regrettable’
November 11, 2014Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel
Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …
Boehringer spends €100 million on inhaler
September 30, 2014Manufacturing and Production, Sales and Marketing Boehringer, Germany, Spiriva, Striverdi, inhaler, olodaterol, respimat
Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the …
Boehringer to slash 600 jobs in native Germany
September 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing AMNOG, Boehringer, Germany, Novartis, cuts, mergers, staff
Boehringer Ingelheim is to cut around 600 of its staff in Germany as part of a drive to reduce costs …
Bayer’s chief executive to step down in 2016
June 4, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Germany, Marijn Dekkers
Marijn Dekkers the chief executive of German pharma firm Bayer has set his departure date to the end of 2016. …
German law could see pharma discounts published
February 18, 2014Sales and Marketing AMNOG, Germany, IMS, NICE, prices
Pharma companies are apprehensive about German lawmakers opening Pandora’s Box this week if they go ahead with plans to publish …
Germany focus: strength with control
February 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMNOG, EFPIA, Germany, IQWIG, NHS, NICE
Germany is the biggest pharmaceutical market in Europe and one of the biggest in the world, but new systems and …
German regulator assesses more drugs
April 22, 2013Sales and Marketing AMNOG, Bayer, Germany, Pradaxa, Xarelto
A new raft of drugs which will be subject to potentially stringent cost/benefit analysis in Germany has been announced. The …
Germany dismisses Seroquel XR
November 14, 2012Sales and Marketing AstraZeneca, FDA, Germany, Seroquel XR
AstraZeneca has received another dent in its international attempts to keep the money-spinning antipsychotic Seroquel going in a new form. …
Pharma calls for urgent change in German system
June 8, 2012Sales and Marketing AMNOG, EFPIA, Germany, Trajenta, VFA
Europe’s pharma industry has called on the German government to re-think its approach to pricing, saying it is could cause …
Boehringer-Lilly won’t launch Trajenta in Germany
September 5, 2011Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts
Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …
Lilly chief: German reforms jeopardise pharma innovation
July 8, 2011Research and Development, Sales and Marketing Germany, John Lechleiter, lilly, medicines pricing
German healthcare spending cuts have gone too far and risk jeopardising pharmaceutical innovation in the country, according to Lilly’s chief …
IDT Biologika expands investment in German manufacturing capacity
March 28, 2011Manufacturing and Production Germany, IDT Biologika, vaccines
IDT Biologika has said it plans to invest around 85 million euros in new production facilities and equipment in Germany …
Bayer invests 35m euros in biologics production
December 14, 2010Manufacturing and Production Bayer, Germany, biologics, clinical trials supplies, pharma production
Bayer HealthCare is ramping up its biologics production capacity with the building of a new facility in Wuppertal, Germany, that …
Germany to cut drug prices by 2 billion euro
November 12, 2010Sales and Marketing Cornelia Yzer, GKV-Spitzenverband, Germany, IQWIG, Philipp Rosler, VFA, health insurers, healthcare spending, innovative medicines
The lower house of the German Parliament has passed a new law to control the cost of new prescription medicines. …
German rebates to cost pharma 1 billion euro
November 1, 2010Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs
The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
